Scholarlink

Background <p>Sarcoidosis is a multisystem granulomatous disease of unknown etiology, with pulmonary involvement being the most common and clinically significant manifestation. Vascular adhesion protein-1 (VAP-1) plays a key role in leukocyte trafficking to inflamed tissues. [⁶⁸Ga]Ga-DOTA-Siglec-9 is a novel PET radiotracer that binds to VAP-1. This proof-of-concept study aimed to evaluate the feasibility of [<sup>68</sup>Ga]Ga-DOTA-Siglec-9 PET/CT for imaging pulmonary sarcoidosis.</p> Methods <p>Six patients with stage 2 pulmonary sarcoidosis (age 50.5 ± 13.1 years; bodyweight 84.2 ± 14.7&#xa0;kg), diagnosed by clinical, radiological, and histological findings, underwent [<sup>68</sup>Ga]Ga-DOTA-Siglec-9 PET/CT. Control subjects included six healthy male volunteers (age 37.5 ± 10.3 years; bodyweight 80.3 ± 3.9&#xa0;kg) and one female patient with lung cancer (age 77 years; bodyweight 62&#xa0;kg). Tracer uptake was quantified in the lungs, mediastinal lymph nodes, and organs involved in systemic inflammation.</p> Results <p>Patients with sarcoidosis showed significantly higher [<sup>68</sup>Ga]Ga-DOTA-Siglec-9 uptake in the lungs (SUV<sub>mean</sub> 1.82 ± 0.52 vs. 0.41 ± 0.08; <i>P</i> = 0.00006) and mediastinal lymph nodes (SUV<sub>mean</sub> 2.06 ± 0.46 vs. 0.89 ± 0.26; <i>P</i> = 0.0003) compared to healthy controls. Increased uptake was also observed in the liver (SUV<sub>mean</sub> 1.18 ± 0.14 vs. 0.80 ± 0.10, <i>P</i> = 0.0003), spleen (SUV<sub>mean</sub> 1.13 ± 0.09 vs. 0.82 ± 0.06, <i>P</i> = 0.00003), bone marrow (SUV<sub>mean</sub> 0.30 ± 0.12 vs. 0.06 ± 0.05, <i>P</i> = 0.001), and bone (SUV<sub>mean</sub> 0.27 ± 0.11 vs. 0.08 ± 0.04, <i>P =</i> 0.004), indicating systemic inflammation.</p> Conclusions <p>This proof-of-concept study demonstrates the potential of VAP-1-targeted [<sup>68</sup>Ga]Ga-DOTA-Siglec-9 PET/CT for imaging pulmonary sarcoidosis and associated inflammatory activity. Further validation in larger cohorts is warranted.</p> Trial registration <p>ClinicalTrials.gov, NCT03755245 (registered 27 November 2018), NCT05212103 (registered 27 January 2022).</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [68Ga]Ga-DOTA-Siglec-9

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月19日

查看全文
  • Prince Dadson,
  • Heli Ylä-Outinen,
  • Kari Kalliokoski,
  • Terhi Tuokkola,
  • Simona Malaspina,
  • Mikko Koivumäki,
  • Riikka Viitanen,
  • Noora Rajala,
  • Maria Silvoniemi,
  • Tuula Tolvanen,
  • Pirjo Nuutila,
  • Sirpa Jalkanen,
  • Antti Saraste,
  • Tarja Saaresranta,
  • Pekka Taimen,
  • Anne Roivainen

摘要

Background

Sarcoidosis is a multisystem granulomatous disease of unknown etiology, with pulmonary involvement being the most common and clinically significant manifestation. Vascular adhesion protein-1 (VAP-1) plays a key role in leukocyte trafficking to inflamed tissues. [⁶⁸Ga]Ga-DOTA-Siglec-9 is a novel PET radiotracer that binds to VAP-1. This proof-of-concept study aimed to evaluate the feasibility of [68Ga]Ga-DOTA-Siglec-9 PET/CT for imaging pulmonary sarcoidosis.

Methods

Six patients with stage 2 pulmonary sarcoidosis (age 50.5 ± 13.1 years; bodyweight 84.2 ± 14.7 kg), diagnosed by clinical, radiological, and histological findings, underwent [68Ga]Ga-DOTA-Siglec-9 PET/CT. Control subjects included six healthy male volunteers (age 37.5 ± 10.3 years; bodyweight 80.3 ± 3.9 kg) and one female patient with lung cancer (age 77 years; bodyweight 62 kg). Tracer uptake was quantified in the lungs, mediastinal lymph nodes, and organs involved in systemic inflammation.

Results

Patients with sarcoidosis showed significantly higher [68Ga]Ga-DOTA-Siglec-9 uptake in the lungs (SUVmean 1.82 ± 0.52 vs. 0.41 ± 0.08; P = 0.00006) and mediastinal lymph nodes (SUVmean 2.06 ± 0.46 vs. 0.89 ± 0.26; P = 0.0003) compared to healthy controls. Increased uptake was also observed in the liver (SUVmean 1.18 ± 0.14 vs. 0.80 ± 0.10, P = 0.0003), spleen (SUVmean 1.13 ± 0.09 vs. 0.82 ± 0.06, P = 0.00003), bone marrow (SUVmean 0.30 ± 0.12 vs. 0.06 ± 0.05, P = 0.001), and bone (SUVmean 0.27 ± 0.11 vs. 0.08 ± 0.04, P = 0.004), indicating systemic inflammation.

Conclusions

This proof-of-concept study demonstrates the potential of VAP-1-targeted [68Ga]Ga-DOTA-Siglec-9 PET/CT for imaging pulmonary sarcoidosis and associated inflammatory activity. Further validation in larger cohorts is warranted.

Trial registration

ClinicalTrials.gov, NCT03755245 (registered 27 November 2018), NCT05212103 (registered 27 January 2022).

Graphical abstract